Lipoprotein (a) and lipid-lowering treatment from the perspective of a cardiac surgeon. An impact on the prognosis in patients with aortic valve replacement and after heart transplantation

IF 1.9 Q3 PERIPHERAL VASCULAR DISEASE

International Journal of Cardiology Cardiovascular Risk and Prevention Pub Date : 2024-06-06 DOI:10.1016/j.ijcrp.2024.200297

Stanisław Surma , Michał O. Zembala , Bogusław Okopień , Maciej Banach

{"title":"Lipoprotein (a) and lipid-lowering treatment from the perspective of a cardiac surgeon. An impact on the prognosis in patients with aortic valve replacement and after heart transplantation","authors":"Stanisław Surma , Michał O. Zembala , Bogusław Okopień , Maciej Banach","doi":"10.1016/j.ijcrp.2024.200297","DOIUrl":null,"url":null,"abstract":"<div><p>Lipoprotein(a) is a recognized risk factor for ASCVD. There is still no targeted therapy for Lp(a), however, drugs such as pelacarsen, olpasiran, zerlasiran, lepodisiran and muvalaplin are in clinical trials and have been shown to be effective in significantly reducing Lp(a) levels. Moreover, elevated Lp(a) levels significantly affect the prognosis of patients after aortic valve replacement (AVR) and heart transplantation (HTx). Therefore, the assessment of Lp(a) concentration in these patients will allow for a more accurate stratification of their cardiovascular risk, and the possibility of lowering Lp(a) will allow for the optimization of this risk. In this article, we summarized the most important information regarding the role of Lp(a) and lipid-lowering treatment in patients after AVR and HTx.</p></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"22 ","pages":"Article 200297"},"PeriodicalIF":1.9000,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S277248752400062X/pdfft?md5=ece16801c983d7af3acc1740f98b7385&pid=1-s2.0-S277248752400062X-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Cardiology Cardiovascular Risk and Prevention","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S277248752400062X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Lipoprotein(a) is a recognized risk factor for ASCVD. There is still no targeted therapy for Lp(a), however, drugs such as pelacarsen, olpasiran, zerlasiran, lepodisiran and muvalaplin are in clinical trials and have been shown to be effective in significantly reducing Lp(a) levels. Moreover, elevated Lp(a) levels significantly affect the prognosis of patients after aortic valve replacement (AVR) and heart transplantation (HTx). Therefore, the assessment of Lp(a) concentration in these patients will allow for a more accurate stratification of their cardiovascular risk, and the possibility of lowering Lp(a) will allow for the optimization of this risk. In this article, we summarized the most important information regarding the role of Lp(a) and lipid-lowering treatment in patients after AVR and HTx.

查看原文本刊更多论文

从心脏外科医生的角度看脂蛋白（a）和降脂治疗。对主动脉瓣置换术和心脏移植术后患者预后的影响

脂蛋白（a）是公认的急性心血管疾病的危险因素。目前还没有针对脂蛋白（a）的靶向治疗方法，不过，佩拉卡森、奥帕西兰、泽拉西兰、利波地西兰和缪瓦拉普林等药物已进入临床试验阶段，并被证明能有效显著降低脂蛋白（a）水平。此外，Lp(a)水平升高会严重影响主动脉瓣置换术（AVR）和心脏移植术（HTx）患者的预后。因此，评估这些患者的脂蛋白（a）浓度将有助于更准确地对其心血管风险进行分层，而降低脂蛋白（a）的可能性将有助于优化这种风险。在这篇文章中，我们总结了有关 Lp(a) 和降脂治疗在 AVR 和 HTx 患者中的作用的最重要信息。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Cardiology Cardiovascular Risk and Prevention Cardiology and Cardiovascular Medicine

CiteScore

3.00

自引率

0.00%

发文量

审稿时长

72 days